The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：443

作者：

Yuan, Min ^{[1
,2
]}

Huang, Li-Li ^{[1
,2
]}

Chen, Jian-Hua ^{[1
,3
]}

Wu, Jie ^{[3
,4
]}

Xu, Qing ^{[1
,2
]}

机构：

[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China

[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China

[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA

[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA

来源：

SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;

D O I：

10.1038/s41392-019-0099-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.

引用

页数：14

共 50 条

[41] Emerging antiangiogenic therapies for non-small-cell lung cancer
Blakely, Collin
Jahan, Thierry
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1607 - 1618
[42] Targeted therapies and immunotherapy in non-small-cell lung cancer
Cortinovis, D.
Abbate, M.
Bidoli, P.
Capici, S.
Canova, S.
ECANCERMEDICALSCIENCE, 2016, 10
[43] Immunotherapy combinations emerging in non-small-cell lung cancer
Chao, Yvonne L.
Pecot, Chad V.
IMMUNOTHERAPY, 2018, 10 (08) : 627 - 629
[44] Radiotherapy and targeted therapies in non-small-cell lung cancer
Girard, N.
Mornex, F.
BULLETIN DU CANCER, 2009, 96 (03) : 311 - 319
[45] Emerging targets in advanced non-small-cell lung cancer
Valentino, Francesco
Borra, Gloria
Allione, Paolo
Rossi, Lorena
FUTURE ONCOLOGY, 2018, 14 (13) : 61 - 72
[46] New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer
Zarogoulidis, Paul
Yarmus, Lonny
Zarogoulidis, Konstantinos
THERAPEUTIC DELIVERY, 2013, 4 (10) : 1221 - 1223
[47] Adjuvant therapy for non-small-cell lung cancer
Kalemkerian, Gregory P.
LANCET, 2010, 375 (9722): : 1230 - 1231
[48] Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer
Spaans, Johanna N.
Goss, Glenwood D.
FRONTIERS IN ONCOLOGY, 2014, 4
[49] Maintenance therapy in non-small-cell lung cancer
Schmid-Bindert, Gerald
TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (02) : 105 - 110
[50] Systemic therapy in non-small-cell lung cancer
Jazieh, Abdul-Rahman
Saadeen, Ahmed
ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S97 - S99

← 1 2 3 4 5 →